evaluation process. Relevant data received after this date will be considered during the ICCVAM evaluation process, if feasible. All information submitted in response to this notice will be made publicly available and may be incorporated into future NICEATM and ICCVAM reports and publications as appropriate.

When submitting data, please reference this **Federal Register** notice and provide appropriate contact information (name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization, as applicable).

NICEATM prefers that data be submitted as copies of pages from study notebooks and/or study reports, if available. Raw data and analyses available in electronic format may also be submitted. Each submission for a substance should preferably include the following information, as appropriate:

Common and trade name

• Chemical Abstracts Service Registry Number (CASRN)

• Chemical and/or product class

• Commercial source

• In vivo or in vitro test protocol used

• Individual animal or *in vitro* responses at each observation time (i.e., raw data)

• The extent to which the study complied with national/international Good Laboratory Practice (GLP) guidelines

• Date and testing organization

• Physical and chemical properties (e.g. molecular weight, pH, water solubility, etc.)

## Background Information on ICCVAM and NICEATM

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that use or generate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety and hazards of chemicals and products and that refine, reduce, and replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 2851-3, available at (http:// iccvam.niehs.nih.gov/docs/about\_docs/ PL106545.pdf) established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of Federal agencies. Additional

information about ICCVAM and NICEATM is available on the following Web site: *http://iccvam.niehs.nih.gov.* 

Dated: March 24, 2008.

#### Samuel H. Wilson,

Acting Director, National Institute of Environmental Health Sciences and National Toxicology Program.

[FR Doc. E8–6969 Filed 4–3–08; 8:45 am]

BILLING CODE 4140-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control; Special Emphasis Panel (SEP): Identification, Surveillance and Control of Vector-Borne and Zoonotic Infectious Diseases in Uganda, Funding Opportunity Announcement (FOA) CK08–004

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

*Time and Date:* 12 p.m.–2 p.m., May 16, 2008 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of "Identification, Surveillance and Control of Vector-Borne and Zoonotic Infectious Diseases in Uganda," FOA CK08–004.

Contact Person for More Information: Shoukat Qari, D.V.M., PhD, Scientific Review Administrator, Strategic Science and Program Unit, Office of the Director, Coordinating Center for Infectious Diseases, CDC, 1600 Clifton Road, Mailstop C–19, Atlanta, GA, Telephone (404) 639–8942.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: March 28, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–7032 Filed 4–3–08; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control; Special Emphasis Panel (SEP): Mining Occupational Safety and Health Research (R01), Request for Application (RFA) OH08–003

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

*Times and Dates:* 5 p.m.–7 p.m., May 7, 2008 (Closed). 8 a.m.–5 p.m., May 8, 2008 (Closed). 8 a.m.–5 p.m., May 9, 2008 (Closed).

*Place:* Radisson Plaza-Warwick Hotel Philadelphia, 1701 Locust Street #411, Philadelphia, PA 19103.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463.

*Matters to be Discussed:* The meeting will include the review, discussion, and evaluation of "Mining Occupational Safety and Health Research (R01), RFA OH08–003."

Contact Person for More Information: Charles N. Rafferty, PhD, Assistant Director for Review and Policy Office of Extramural Programs, CDC, 1600 Clifton Road, NE., Mailstop E74, Atlanta, GA 30333, Telephone: (404) 498–2530.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: March 28, 2008.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–7033 Filed 4–3–08; 8:45 am] BILLING CODE 4163–18–P